DEF: Fortrea Holdings Inc. 2026 Annual Meeting Proxy Statement

Fortrea Holdings Inc. is holding its 2026 Annual Meeting of Stockholders virtually on June 9, 2026, to elect directors, ratify auditors, and vote on executive compensation.

Summary

• Fortrea Holdings Inc. is convening its 2026 Annual Meeting of Stockholders virtually on June 9, 2026, at 8:00 a.m. Eastern Time.
• The meeting will address key corporate governance matters, including the election of three Class III Directors: Anshul Thakral, Peter M. Neupert, and William J. Sharbaugh, whose terms will expire in 2028.
• Stockholders will also vote on ratifying the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
• An advisory vote on the compensation of the company's named executive officers (Say-on-Pay) will also be conducted.
• The proxy materials, including the Notice of Internet Availability, proxy statement, and proxy card, were made available to stockholders on or about April 27, 2026.
• Stockholders of record as of April 15, 2026, are entitled to vote, with 94,584,730 shares of Common Stock outstanding.
• The company emphasizes the importance of voting by proxy via phone, internet, or mail to ensure a quorum and save solicitation expenses.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to the reported net loss, decreased Adjusted EBITDA, and negative Total Stockholder Return compared to its peer group, despite the company's efforts in corporate governance and executive compensation alignment.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance oversight.
• The proposed directors have extensive experience in relevant industries, including healthcare, biopharmaceuticals, and technology.
• The Audit Committee has reviewed the 2025 financial statements and recommended their inclusion in the Form 10-K.
• Deloitte & Touche LLP, the proposed independent auditor, has a long-standing relationship with the company.
• The company has a robust corporate governance framework, including a Code of Conduct and Ethics, and committee charters.
• The Board leadership structure separates the Chairman and CEO roles, with an independent Chairman, which is considered optimal.
• The company actively engages with its stockholders, with outreach to approximately 63% of its top 30 active stockholders in 2025.
• The executive compensation program is designed with a pay-for-performance philosophy, aligning executive pay with company and individual results.
• The company has strong stock ownership guidelines for executives and prohibits hedging and pledging of company securities.
• The company has a clawback policy in place to recover incentive compensation in the event of an accounting restatement.

Negatives

• The company reported a net loss from continuing operations of $986.2 million for the twelve months ended December 31, 2025.
• Adjusted EBITDA for the twelve months ended December 31, 2025, was $189.9 million, a decrease from $202.5 million in 2024.
• The company's Total Stockholder Return (TSR) was negative for the period from July 1, 2023, to December 31, 2025, while the peer group TSR was positive.
• The company's Net Income for 2025 was a loss of $989 million, significantly worse than the prior two years.
• The company's 2025 performance for the first tranche of PSUs was below the minimum threshold for Adjusted EBITDA margin and between threshold and target for Revenue.
• Thomas Pike, former CEO, received significant severance payments totaling $3,894,000 in cash and $7,318,116 in RSU accelerations and accrued dividends in 2025.

Risks

• Forward-looking statements are subject to inherent risks and uncertainties, including the possibility of not generating a large number of net new business awards, delays, terminations, or reductions in scope of awards, or failure to go to contract.
• The company may be unable to contract with suitable investigators or recruit and enroll patients for clinical trials.
• International operations could subject the company to additional risks and expenses.
• The company's business and results of operations could be adversely impacted by various risks and uncertainties discussed in its Form 10-K and other SEC filings.
• The staggered terms of the Board of Directors, transitioning to a non-classified board by 2028, may delay or prevent a change in management or control.
• While the company has a cybersecurity risk management program, unknown cybersecurity risks could materialize, including in connection with the implementation of independent systems following the Spin.

Future Outlook

The filing does not contain specific forward-looking financial guidance for future periods. However, it discusses the company's ongoing efforts to streamline operations, strengthen its balance sheet, and achieve cost savings, indicating a focus on operational improvement and financial stability.

Management Comments

• "Whether or not you attend the Annual Meeting, it is important that your shares be represented and voted at the Annual Meeting. Therefore, I urge you to promptly vote and submit your proxy by phone, via the Internet, or, if you received paper copies of these materials, by signing, dating and returning the enclosed proxy card in the enclosed envelope, which requires no postage if mailed in the United States."
• "We believe that the virtual-only meeting format will give stockholders the opportunity to exercise the same rights as if they had attended an in-person meeting and believe that these measures will enhance stockholder access and encourage participation and communication with our Board and management."
• "Our Board believes that this leadership structure, separating the Chairman and Chief Executive Officer roles, is optimal at this time."
• "The MDCC believes this affirms our stockholders support of our approach to executive compensation."
• "The Fortrea Board believes that requiring executive management to maintain a significant personal level of stock ownership ensures that each executive officer is financially aligned with the interests of Fortreas stockholders."

Industry Context

StockSavvy.ai notes that Fortrea Holdings Inc. operates as a global contract research organization (CRO) in the life sciences industry, providing clinical trial management, clinical pharmacology, and consulting services. The company's focus on streamlining biopharmaceutical product and medical device development aligns with the broader industry trend of outsourcing R&D activities to specialized CROs to accelerate drug development and reduce costs.

Comparison to Industry Standards

• The company's peer group for executive compensation benchmarking includes companies like IQVIA Holdings, Inc., Medpace Holdings, Inc., and Charles River Laboratories International, Inc., which are major players in the CRO and life sciences services sector.
• The executive compensation philosophy emphasizes a pay-for-performance structure, utilizing a mix of base salary, annual bonuses, and long-term incentives (PSUs and RSUs), which is a common practice among publicly traded companies in the industry.
• The company's cybersecurity risk management program is based on industry-recognized best practices and standards, including the NIST Cybersecurity Framework (CSF) and ISO 27001:2022.
• The company's financial performance, particularly the net loss and decrease in Adjusted EBITDA in 2025, contrasts with the positive Total Stockholder Return of its peer group during the same period, suggesting potential underperformance relative to industry peers.

Corporate Governance

Related Party Transactions

• Agreements with Labcorp, including a Separation and Distribution Agreement, Transition Services Agreement, Tax Matters Agreement, and Employee Matters Agreement, govern the ongoing relationships post-Spin.

Stakeholder Impact

• Shareholders: Voting on director elections, auditor ratification, and executive compensation; potential impact from financial performance and strategic decisions.
• Employees: Subject to company policies, compensation structures, and potential impacts from operational changes and risk management.
• Customers: Rely on Fortrea for clinical development solutions; impact from service quality and company stability.
• Suppliers: Engage with Fortrea for services and supplies; impact from company's financial health and operational needs.
• Creditors: Fortrea's financial performance and debt levels will impact creditors.

Next Steps

• Election of directors at the Annual Meeting.
• Ratification of the appointment of Deloitte & Touche LLP as independent registered public accounting firm.
• Advisory vote on the compensation of named executive officers.
• The Board will transition to a non-classified board structure starting at the 2028 Annual Meeting.
• Stockholders can submit proposals for the 2027 Annual Meeting by December 28, 2026 (for inclusion in proxy materials) or between February 9, 2027, and March 11, 2027 (for presentation at the meeting).

Key Dates

Recommendation

While the company is addressing key governance and compensation matters, the significant net loss, declining Adjusted EBITDA, and negative TSR relative to peers indicate ongoing financial challenges. The upcoming annual meeting is a procedural event, and investors should monitor future financial performance and strategic execution before considering a more definitive investment stance.

Keywords

Fortrea Holdings Inc., Proxy Statement, Annual Meeting, DEF 14A, Director Election, Independent Auditor, Executive Compensation, Stockholder Vote, Corporate Governance, SEC Filing